Diabetes Linked With Poorer RCC Survival

Article

Among patients with clear cell renal cell carcinoma who had undergone nephrectomy, patients with diabetes were found to have a significantly decreased cancer-specific and overall survival.

Micrograph of clear cell renal cell carcinoma

Micrograph of clear cell RCC; source: Nephron, Wikimedia Commons

Among patients with clear cell renal cell carcinoma (RCC) who had undergone nephrectomy, those patients with diabetes were found to have a significantly decreased cancer-specific and overall survival compared with those patients without diabetes.

“These findings underscore the importance of considering the effect of diabetes mellitus among other comorbidities on outcomes during risk stratification in RCC,” wrote Sarah P. Psutka, MD, of the department of urology at Mayo Clinic, Rochester, Minn., and colleagues in the Journal of Urology.

In recent years, the incidence of both RCC and diabetes has increased, according to information in the study. However, large studies examining the association between diabetes and RCC had been previously lacking.

The study included 1,964 patients who underwent nephrectomy for clear cell RCC between 1990 and 2008. In the group there were 257 patients (13%) with diabetes at the time of surgery who were matched 1:2 to patients without diabetes. The researchers then compared cancer-specific and overall survival.

Patients with diabetes were found to be older, with a greater degree of comorbidity, and were more likely to smoke and have worse performance status.

Among the matched patients, 229 experienced progression of their disease at a median of 1.5 years post-surgery. No significant difference in 5-year progression-free survival was found between patients with diabetes and those without (72% vs 76%).

Cancer-specific survival analysis found that 149 patients died from RCC. In a univariate analysis, there was no statistically significant increase in risk of death from RCC between the two groups. However, a multivariable analysis that adjusted for Charlson comorbidity index and BMI found that patients with diabetes had a 55% increased risk for death from RCC (P = .017).

Finally, the researchers examined differences in overall survival; 393 patients had died at a median of 4.3 years after surgery. Diabetes was found to be significantly associated with an increased risk for all-cause mortality on both the univariate (HR = 1.57; P < .001) and multivariate analysis (HR = 1.32; P = .014).

The researchers noted in their discussion that the retrospective study design limits their ability to test a causal relationship between diabetes and decreased overall survival.

“The results from this matched cohort study support the preexisting evidence from prior retrospective cohort studies: that diabetes mellitus is independently associated with inferior outcomes in patients with RCC, specifically for clear cell RCC patients,” the researchers wrote. “At this time, additional research is needed to determine whether this effect is associated with diabetic severity and, as such, if this impact may be mitigated with tighter glycemic control.”

Recent Videos
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Related Content